Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Raises $30M in Equity Funding

NEW YORK – Syapse said on Thursday that it has landed $30 million in new equity investments. Revelation Alpine led the round, with participation from previous investors Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance, Safeguard Scientifics, and Social Capital. 

As a result of the investment, Revelation Alpine Managing Partner Zack Scott has been named to the Syapse board of directors. 

Syapse, a San Francisco-based maker of software to support precision oncology care and drug discovery, did not name this round of venture capital, but the company raised $30 million in a Series D round in November 2017. The Stanford University spinoff has landed at least $98 million in venture investments since its inception in 2014.  

The firm works with life science companies to provide analytics via "real-world" clinical, molecular, and outcomes data to support R&D, clinical trial matching, regulatory filings, post-approval monitoring, and treatment decisions.

"We are in an unprecedented time that has further highlighted the urgent need for new tools in the delivery of care to patients facing challenging and chronic health conditions, including cancer," Henry Ford Medical Group CEO Steve Kalkanis said in a statement. "This financing is another step forward in support of our collaboration with Syapse to advance the use of real-world data and precision medicine in improving outcomes for patients."  

Detroit-based Henry Ford Health System launched its precision oncology program in 2016 with the help of Syapse  

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.